| T24 |
50, 100, 150, 200, 250, 300 µM for 12, 24 or 48 h |
Apoptosis Cell cycle arrest at G1 phase |
↓p-AKT, ↓Bcl-2, ↓Bcl-xL, ↑Bax, ↓p-Bad, ↑cleaved caspase 3, ↑cleaved PARP ↑p21, ↑p-p38. ↓cyclin D1, ↓CDK4, ↓p-Rb |
Bai et al., 2010Bai Y, Mao QQ, Qin J, Zheng XY, Wang YB, Yang K, Shen HF and Xie LP (2010) Resveratrol induces apoptosis and cell cycle arrest of human T24 bladder cancer cells in vitro and inhibits tumor growth in vivo. Cancer Sci 101:488-493.
|
| BTT739 and T24 |
12.5, 25, 50, 100 µM for 24 h or 50 µM for 6, 12, 24 or 48 h |
Apoptosis |
↑ROS production, mitochondrial membrane potential disruption, release of cytocrome c, ↑caspase 9, ↑caspase 3 |
Lin et al., 2012Lin X, Wu G, Huo WQ, Zhang Y and Jin FS (2012) Resveratrol induces apoptosis associated with mitochondrial dysfunction in bladder carcinoma cells. Int J Urol 19:757-764.
|
| ECV304 (derivation from T24) |
0.1, 0.5, 1, 2.5, 5, 25, 50, 100 µM for 6 h 30 min or 50 µM for 12, 24 or 48 h |
↑cell permeability and ↑DNA fragmentation Apoptosis |
↑ROS production ↓Bad/Bcl-2 ratio |
Stocco et al., 2012Stocco B, Toledo K, Salvador M, Paulo M, Koyama N and Toloi MRT (2012) Dose-dependent effect of resveratrol on bladder cancer cells: chemoprevention and oxidative stress. Maturitas 72:72-78.
|
| EJ |
100, 150, 200 µM for 1, 1.5 or 2 h in 24 h intervals during 72 h |
↓cell growth and cell cycle arrest at S phase Apoptosis |
↓STAT3, ↓p-STAT3, ↓p-STAT3 nuclear translocation, ↓c-Myc, ↓cyclin-D1, ↓survivin, ↓VEGF - |
Wu et al., 2014Wu ML, Li H, Yu LJ, Chen XY, Kong QY, Song X, Shu XH and Liu J (2014) Short-term resveratrol exposure causes in vitro and in vivo growth inhibition and apoptosis of bladder cancer cells. PLoS One 9:e89806.
|
| T24 and 5637 |
10, 30, 50 µM for 48 h. |
Apoptosis |
↓miR-21, ↓p-Akt, ↓Bcl-2 |
Zhou et al., 2014Zhou C, Ding J and Wu Y (2014) Resveratrol induces apoptosis of bladder cancer cells via miR‑21 regulation of the Akt/Bcl‑2 signaling pathway. Mol Med Rep 9:1467-1473.
|
| T24 |
10, 25, 50, 100 µM for 6, 12 or 24 h |
↓cell adhesion ↓cell migration and ↓cell invasion |
- ↓p-JNK1/2, ↓p-ERK1/2, ↓MMP‑2, ↓MMP‑9 |
Bai et al., 2017Bai Y, Yang H, Zhang G, Hu L, Lei Y, Qin Y, Yang Y, Wang Q, Li R and Mao Q (2017) Inhibitory effects of resveratrol on the adhesion, migration and invasion of human bladder cancer cells. Mol Med Rep 15:885-889.
|
| Pumc‑91/ADM |
50, 100, 150, 200, 250, 300, 350 µM for 4, 48 or 72 h, |
Sensitized Adriamycin-resistant cells Cell cycle arrest at S phase |
↓MRP1, ↓LRP, ↓GST, ↑Topo-II - |
Wang et al., 2017Wang S, Meng Q, Xie Q and Zhang M (2017) Effect and mechanism of resveratrol on drug resistance in human bladder cancer cells. Mol Med Rep 15:1179-1187.
|
| T24 and EJ |
20, 40, 60, 80, 100, 150, 200 µM for 6, 12, 24, 48 or 72h |
Cell cycle arrest at G1 phase |
- |
Yang et al., 2017Yang Y, Li C, Li H, Wu M, Ren C, Zhen Y, Ma X, Diao Y, Ma X, Deng S et al., (2017) Differential sensitivities of bladder cancer cell lines to resveratrol are unrelated to its metabolic profile. Oncotarget 8:40289-40304.
|
| RT4, 5637 and T24 |
12.5, 25, 50, 100, 150, 200, 250 µM for 24 h |
↓cell proliferation ↓clonogenic survival Morphological changes Cell cycle arrest at phase S (5637 and T24) Apoptosis (RT4) Necrosis (T24) Antiproliferative effects |
↑primary DNA damage ↓PLK1 - ↓PLK1 ↓AKT, ↓mTOR, ↓SRC - ↑RASSF1A/↓HOXB3 (T24), ↓DNMT1 (RT4) |
Almeida et al., 2019Almeida TC, Guerra CCC, de Assis BLG, de Oliveira Aguiar Soares RD, Garcia CCM, Lima AA and da Silva GN (2019) Antiproliferative and toxicogenomic effects of resveratrol in bladder cancer cells with different TP53 status. Environ Mol Mutagen 60:740-751.
|
| T24 |
25, 50, 75, 100, 125, 150, 200 µM for 6, 12, 24, 48 or 72 h |
Apoptosis Morphological changes |
- - |
Yang et al., 2019Yang Y, Zhang G, Li C, Wang S, Zhu M, Wang J, Yue H, Ma X, Zhen Y and Shu X (2019) Metabolic profile and structure-activity relationship of resveratrol and its analogs in human bladder cancer cells. Cancer Manag Res 11:4631-4642.
|
Thumbnail
Thumbnail
